Center for Drug Evaluation and Research, United States Food and Drug Administration, 10903 New Hampshire Ave, Silver Spring, Maryland, 20993, USA.
AAPS J. 2017 Jul;19(4):1071-1083. doi: 10.1208/s12248-017-0084-6. Epub 2017 Apr 18.
The Nanotechnology Risk Assessment Working Group in the Center for Drug Evaluation and Research (CDER) within the United States Food and Drug Administration (FDA) was established to assess the potential impact of nanotechnology on drug products. One of the working group's major initiatives has been to conduct a comprehensive risk management exercise regarding the potential impact of nanomaterial pharmaceutical ingredients and excipients on drug product quality, safety, and efficacy. This exercise concluded that current review practices and regulatory guidance are capable of detecting and managing the potential risks to quality, safety, and efficacy when a drug product incorporates a nanomaterial. However, three risk management areas were identified for continued focus during the review of drug products containing nanomaterials: (1) the understanding of how to perform the characterization of nanomaterial properties and the analytical methods used for this characterization, (2) the adequacy of in vitro tests to evaluate drug product performance for drug products containing nanomaterials, and (3) the understanding of properties arising from nanomaterials that may result in different toxicity and biodistribution profiles for drug products containing nanomaterials. CDER continues to actively track the incorporation of nanomaterials in drug products and the methodologies used to characterize them, in order to continuously improve the readiness of our science- and risk-based review approaches. In parallel to the risk management exercise, CDER has also been supporting regulatory research in the area of nanotechnology, specifically focused on characterization, safety, and equivalence (between reference and new product) considerations. This article provides a comprehensive summary of regulatory and research efforts supported by CDER in the area of drug products containing nanomaterials and other activities supporting the development of this emerging technology.
美国食品和药物管理局(FDA)药物评价和研究中心(CDER)的纳米技术风险评估工作组旨在评估纳米技术对药物产品的潜在影响。该工作组的主要举措之一是针对纳米材料药物成分和赋形剂对药物产品质量、安全性和疗效的潜在影响进行全面的风险管理。这项工作得出的结论是,当药物产品中包含纳米材料时,现行的审评实践和监管指南能够发现和管理质量、安全性和疗效的潜在风险。然而,在审评含有纳米材料的药物产品时,仍有三个风险管理领域需要继续关注:(1)了解如何进行纳米材料特性的表征以及用于该特性表征的分析方法;(2)评估含有纳米材料的药物产品的药物产品性能的体外试验是否充分;(3)了解可能导致含有纳米材料的药物产品产生不同毒性和生物分布特征的纳米材料特性。CDER 继续积极跟踪药物产品中纳米材料的纳入情况和用于对其进行表征的方法,以便不断改进我们基于科学和风险的审评方法的准备情况。与风险管理工作同时进行的是,CDER 还一直在支持纳米技术领域的监管研究,特别是侧重于特性描述、安全性和等效性(参考产品和新产品之间)的考虑因素。本文全面总结了 CDER 在含有纳米材料的药物产品领域以及支持这一新兴技术发展的其他活动中所支持的监管和研究工作。